What is B. Riley’s Forecast for VRDN FY2024 Earnings?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Stock analysts at B. Riley decreased their FY2024 EPS estimates for Viridian Therapeutics in a research report issued to clients and investors on Monday, November 18th. B. Riley analyst K. Patel now expects that the company will earn ($4.01) per share for the year, down from their previous forecast of ($3.80). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.04) per share. B. Riley also issued estimates for Viridian Therapeutics’ FY2025 earnings at ($4.82) EPS, FY2026 earnings at ($4.91) EPS, FY2027 earnings at ($3.67) EPS and FY2028 earnings at ($2.23) EPS.

Several other brokerages have also recently commented on VRDN. HC Wainwright increased their target price on shares of Viridian Therapeutics from $27.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. Oppenheimer restated an “outperform” rating and set a $28.00 target price (down previously from $31.00) on shares of Viridian Therapeutics in a report on Monday, August 12th. Royal Bank of Canada restated an “outperform” rating and set a $44.00 target price on shares of Viridian Therapeutics in a report on Thursday, September 19th. BTIG Research increased their target price on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a report on Thursday, September 26th. Finally, Needham & Company LLC restated a “buy” rating and set a $38.00 target price on shares of Viridian Therapeutics in a report on Wednesday, November 13th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $36.33.

Viridian Therapeutics Stock Performance

Shares of VRDN opened at $19.62 on Wednesday. Viridian Therapeutics has a 12 month low of $11.40 and a 12 month high of $27.20. The firm has a fifty day simple moving average of $22.77 and a 200 day simple moving average of $17.13. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -4.55 and a beta of 1.10. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.08 million.

Insider Transactions at Viridian Therapeutics

In related news, CEO Stephen F. Mahoney bought 21,400 shares of the business’s stock in a transaction dated Friday, September 27th. The stock was bought at an average price of $23.33 per share, for a total transaction of $499,262.00. Following the purchase, the chief executive officer now owns 21,400 shares in the company, valued at $499,262. This represents a ? increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Thomas W. Beetham purchased 5,000 shares of the stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average cost of $23.41 per share, for a total transaction of $117,050.00. Following the completion of the transaction, the chief operating officer now owns 6,000 shares of the company’s stock, valued at $140,460. This trade represents a 500.00 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 1,626,400 shares of company stock worth $30,616,312. 0.65% of the stock is owned by insiders.

Hedge Funds Weigh In On Viridian Therapeutics

Hedge funds have recently bought and sold shares of the company. Quest Partners LLC increased its holdings in Viridian Therapeutics by 344.0% in the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock valued at $79,000 after buying an additional 4,692 shares during the period. Ameritas Investment Partners Inc. grew its holdings in shares of Viridian Therapeutics by 19.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after purchasing an additional 799 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Viridian Therapeutics during the 3rd quarter valued at approximately $149,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Viridian Therapeutics by 24.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock valued at $156,000 after purchasing an additional 2,359 shares during the last quarter. Finally, AlphaCentric Advisors LLC grew its holdings in shares of Viridian Therapeutics by 108.3% during the 2nd quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company’s stock valued at $163,000 after purchasing an additional 6,500 shares during the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.